What are the latest funding news in the longevity market? (October 2026)
Building a startup or looking for your next investment in longevity? Our report gives you the full picture.
Longevity funding in 2026 is spreading across two distinct models: science-driven therapeutics that target aging biology and commercial preventive-health platforms designed to help people stay healthier for longer.
The 12 latest qualifying deals in our dataset raised about $833 million combined, although Neko Health's exceptional $700 million Series C accounts for most of that capital.
The market remains geographically diverse, with recent financing going to companies across the United States, Europe, India, the UAE, Singapore and Australia.
And if you want to better understand this new industry, you can download our pitch covering the longevity market.
Insights
- The 12 latest longevity market deals represent roughly $833 million in disclosed financing, but Neko Health alone contributed about 84% of the total, showing how one scaled preventive-health company can distort headline funding figures.
- Seven of the 12 companies are primarily preventive-health, longevity-clinic or diagnostic platforms, while five focus more directly on therapeutics or aging biology, highlighting the market's growing split between care delivery and biotechnology.
- The median financing in this group is only about $8.5 million, despite the $700 million Neko Health round, suggesting that most longevity startups are still raising relatively conventional seed and early-stage venture rounds.
- Six of the 12 companies raised $7 million or less, showing that a large part of the longevity market remains early-stage even as a small number of companies begin attracting growth-scale capital.
- Preventive-health startups increasingly combine several data sources rather than selling a single test, with blood biomarkers, imaging, genomics, wearables and AI appearing repeatedly across the newest longevity funding deals.
- Biological-age measurement is becoming a commercial product feature rather than only a research tool, appearing in companies such as Vytalyou, Axo Longevity and SONATA as part of ongoing preventive-health memberships.
- Geographic expansion is a major use of proceeds for commercial longevity companies: Vytalyou, Axo Longevity, Ahead Health, Neko Health and Everlab are all using fresh capital to enter new cities or countries.
- The therapeutic side of longevity remains predominantly preclinical, with HexemBio, ARTAN Bio, Gero and Reservoir Neuroscience still working toward clinical validation rather than generating revenue from approved aging therapies.
- Longevity funding is no longer concentrated only in Silicon Valley biotech: recent rounds include India, Dubai, Switzerland, Australia, Singapore and multiple European markets, reflecting increasingly global demand for healthspan-focused products.
Written by the New Market Pitch teamWe track new markets so founders and investors can move faster. About us
We follow every new valuation in this market. Find out who's winning the race in our longevity market report.
Summary table of the latest funding deals in the longevity market as of October 2026
We define the longevity market as products and services that use science, medicine, or technology to extend healthy years of life and slow or improve the effects of aging.
We include therapies, diagnostics, clinics, digital tools, supplements, and programs that are explicitly designed and marketed to improve healthspan, prevent age-related decline, or optimize long-term health.
We exclude generic healthcare, wellness, beauty, fitness, eldercare, and financial products that serve older adults but are not specifically focused on longevity or healthspan.
| Name | When | Amount in $ | Round Type | Category |
|---|---|---|---|---|
| Vytalyou | 17 September 2026 | ~$1M | Pre-Series A / Growth | Longevity Clinics & Diagnostics |
| HexemBio | 15 September 2026 | $15.5M reported | Early-stage follow-on | Stem-Cell Rejuvenation |
| Axo Longevity | 15 September 2026 | $5M | Seed | Biological-Age Diagnostics & Preventive Health |
| Longevium | 3 August 2026 | $7M | First financing / Seed | Longevity Clinics & Longevity R&D |
| Ahead Health | 29 July 2026 | $10M | Early-stage follow-on | Preventive Health & Longevity Diagnostics |
| Neko Health | 15 July 2026 | $700M | Series C | Preventive Scanning & Longevity Clinics |
| SONATA | 14 July 2026 | $7M | Seed | Genomics & Personalized Preventive Medicine |
| ARTAN Bio | 1 July 2026 | $1M | Seed | Longevity Therapeutics & Aging Biology |
| Rapalogix Health | 23 June 2026 | $20M | Series A | Longevity Dermatology & Therapeutics |
| Gero | 17 June 2026 | $17M | Equity / Series B | AI Geroscience & Longevity Drug Discovery |
| Reservoir Neuroscience | 17 June 2026 | $3M | Seed Extension | Aging-Brain Therapeutics |
| Everlab | 17 June 2026 | ~$46M | Series A | Preventive Health & Longevity Platform |
All the latest funding deals in the longevity market as of October 2026
Vytalyou raised about $1 million in growth funding in September 2026.
When was it?
Vytalyou's financing was publicly reported on 17 September 2026, after the investment had been secured in August.
Who are they?
Vytalyou runs physician-led longevity clinics combining blood tests, imaging and cardiovascular diagnostics with AI-supported healthspan assessments and personalized interventions.
Geographical focus?
Vytalyou is focused on India, starting with Mumbai clinics in Powai, Juhu and Worli before a planned expansion into other major Indian cities.
Why do we include them in the longevity market?
Vytalyou belongs to the longevity market under longevity clinics and diagnostics because its clinical program explicitly measures biological aging and aims to extend healthspan.
What is the company stage?
Vytalyou is at an early commercial growth stage, with patients already using its first clinic and additional locations being opened.
How much did they raise?
Vytalyou raised approximately ₹8 million to ₹10 crore, with ₹9 crore commonly reported, equivalent to roughly $1 million.
What round is it?
Vytalyou described the financing as growth funding, while the deal is also commonly characterized as a pre-Series A round.
Why did they raise?
Vytalyou raised the capital to open more Mumbai clinics and prepare for expansion into other major Indian cities during 2027.
Is investor excitement matched by real public interest? Find out in our longevity market report.
HexemBio reported $15.5 million in funding for its stem-cell rejuvenation platform in September 2026.
When was it?
HexemBio announced the financing and expansion of its platform on 15 September 2026, with further investment details reported later that month.
Who are they?
HexemBio develops therapies that place aged blood-forming stem cells in a synthetic youthful developmental environment to restore healthier blood and immune-cell production.
Geographical focus?
HexemBio is a U.S.-based biotechnology company operating from New York and Berkeley, with initial clinical development planned in the United States.
Why do we include them in the longevity market?
HexemBio fits the longevity therapeutics and stem-cell rejuvenation category because its core technology directly targets age-related decline in hematopoietic stem cells.
What is the company stage?
HexemBio is at the advanced preclinical and IND-enabling stage and is targeting first-in-human clinical development in 2027.
How much did they raise?
HexemBio reported $15.5 million in funding, although reporting leaves some ambiguity over how much of that figure represents fresh capital versus cumulative funding.
What round is it?
HexemBio's financing was an early-stage follow-on round without a clearly disclosed new Series label.
Why did they raise?
HexemBio raised capital to move its lead rejuvenated stem-cell therapy toward human trials and develop injectable and skin-focused applications of the platform.
Axo Longevity raised a $5 million Seed round in September 2026.
When was it?
Axo Longevity announced the Seed financing on 15 September 2026.
Who are they?
Axo Longevity offers a preventive-health membership using extensive blood testing, biological-age measurement, personalized recommendations, wearable data and an AI health copilot.
Geographical focus?
Axo Longevity is focused primarily on Europe, including the UK, Ireland, Spain, Germany and the Netherlands, with an additional presence in Peru.
Why do we include them in the longevity market?
Axo Longevity fits the longevity diagnostics and preventive-health category because biological-age tracking and long-term health optimization are central to the product.
What is the company stage?
Axo Longevity is at an early commercial growth stage, with operations across several countries, a large laboratory network and growing consumer demand.
How much did they raise?
Axo Longevity raised $5 million in this financing.
What round is it?
Axo Longevity's financing was an oversubscribed Seed round.
Why did they raise?
Axo Longevity raised the capital to expand its laboratory network, develop its AI health copilot, add wearable integrations and scale across Europe.
Not every part of this market gets the same attention from investors. Our longevity market report shows where the money goes.
Longevium raised $7 million in its first investment round in August 2026.
When was it?
Longevium's financing was first publicly reported on 3 August 2026.
Who are they?
Longevium operates longevity clinics and is building an AI research platform for biological-age measurement, digital twins, regenerative medicine and preventive-health technologies.
Geographical focus?
Longevium is centered on Dubai and the UAE, with a broader ambition to serve the MENA longevity market.
Why do we include them in the longevity market?
Longevium fits longevity clinics and longevity R&D because its services and research are explicitly designed to measure biological aging and extend healthy lifespan.
What is the company stage?
Longevium is in commercial growth while simultaneously building out its research infrastructure, with operating clinics and a dedicated longevity AI laboratory under development.
How much did they raise?
Longevium raised $7 million in its first institutional investment round.
What round is it?
Longevium's financing was its first investment round and is commonly described as Seed-stage capital.
Why did they raise?
Longevium raised the funding to build its Dubai Science Park research laboratory and develop new diagnostics, digital twins and regenerative-health technologies.
Ahead Health raised $10 million to expand its preventive-health platform in July 2026.
When was it?
Ahead Health announced the financing on 29 July 2026, with wider funding coverage published the following day.
Who are they?
Ahead Health combines whole-body MRI, advanced blood panels, medical history and AI into recurring physician-reviewed preventive-health assessments.
Geographical focus?
Ahead Health began in Switzerland and is expanding across Europe, starting with Germany and the Netherlands.
Why do we include them in the longevity market?
Ahead Health fits preventive health and longevity diagnostics because the platform focuses on longitudinal monitoring, early risk detection and long-term health optimization.
What is the company stage?
Ahead Health is at an early PMF and commercial expansion stage, with an established Swiss network and its first international markets launching.
How much did they raise?
Ahead Health raised $10 million, equivalent to approximately €8.7 million at the time of the announcement.
What round is it?
Ahead Health's financing was an early-stage follow-on venture round without a newly announced Series label.
Why did they raise?
Ahead Health raised the capital to expand across Germany and the Netherlands while adding medical partners and developing its technology platform.
We track how fast challengers are gaining on the incumbents. Our longevity market report covers every player worth watching.
Neko Health raised a $700 million Series C in July 2026.
When was it?
Neko Health announced the Series C financing on 15 July 2026.
Who are they?
Neko Health operates preventive-health centers using proprietary full-body scanning, blood testing and clinician review to detect health risks before serious disease develops.
Geographical focus?
Neko Health started in Sweden, expanded significantly in the UK and is now entering the United States.
Why do we include them in the longevity market?
Neko Health fits preventive scanning and longevity clinics because its recurring assessments are designed around proactive risk detection and maintaining long-term health.
What is the company stage?
Neko Health is a scaled growth-stage company, with more than 100,000 scans completed and significant demand across its existing markets.
How much did they raise?
Neko Health raised $700 million in this financing.
What round is it?
Neko Health's financing was a Series C round that valued the company at approximately $7 billion.
Why did they raise?
Neko Health raised the capital primarily to fund its U.S. launch, expand its clinic network and continue investing in scanning technology and medical research.
SONATA raised a $7 million Seed round as it launched in July 2026.
When was it?
SONATA's $7 million financing was reported on 14 July 2026 alongside the company's launch.
Who are they?
SONATA offers physician-led preventive care combining whole-genome sequencing, more than 140 biomarkers, DNA-methylation testing, wearable data and clinical AI.
Geographical focus?
SONATA is initially focused on the United States, starting with New York, San Francisco and Los Angeles.
Why do we include them in the longevity market?
SONATA belongs to longevity diagnostics and personalized preventive medicine because biological-age measurement and long-term physician-led risk prevention are central to its membership.
What is the company stage?
SONATA is at the product launch and early commercial stage.
How much did they raise?
SONATA raised $7 million in its latest financing.
What round is it?
SONATA's financing was a Seed round.
Why did they raise?
SONATA raised the funding to launch its membership in major U.S. cities, expand its physician-led care model and continue building its clinical AI infrastructure.
ARTAN Bio raised a $1 million Seed round in July 2026.
When was it?
ARTAN Bio announced the financing on 1 July 2026, with independent business coverage following on 2 July.
Who are they?
ARTAN Bio develops engineered transfer-RNA therapies designed to suppress harmful stop-codon mutations and restore normal protein production in aging-related biology.
Geographical focus?
ARTAN Bio is based in St. Petersburg, Florida, and is developing its initial programs for U.S. clinical development.
Why do we include them in the longevity market?
ARTAN Bio fits longevity therapeutics and aging biology because its core platform explicitly targets mutations that accumulate with age and contribute to age-related decline.
What is the company stage?
ARTAN Bio is a preclinical company moving toward IND-enabling development and eventual first-in-human studies.
How much did they raise?
ARTAN Bio raised $1 million in this financing.
What round is it?
ARTAN Bio's financing was a Seed round.
Why did they raise?
ARTAN Bio raised the funding to complete additional preclinical work, scale manufacturing inputs and prepare its platform for human studies.
Failures teach as much as successes. We break down the biggest falls in our longevity market report.
Rapalogix Health raised a $20 million Series A in June 2026.
When was it?
Rapalogix Health announced the Series A financing on 23 June 2026.
Who are they?
Rapalogix Health develops molecules, dermatology products and prescription candidates that target cellular pathways involved in biological skin aging.
Geographical focus?
Rapalogix Health is focused initially on the United States, including distribution through American dermatology practices.
Why do we include them in the longevity market?
Rapalogix Health fits longevity dermatology and therapeutics because its products target biological mechanisms of cellular aging rather than only the visible appearance of older skin.
What is the company stage?
Rapalogix Health combines commercial growth with preclinical drug development, with Re-Q already commercial and prescription programs still moving toward the clinic.
How much did they raise?
Rapalogix Health raised $20 million in this financing.
What round is it?
Rapalogix Health's financing was a Series A round.
Why did they raise?
Rapalogix Health raised the capital to expand Re-Q nationally and fund IND-enabling development of RLX-202 and additional longevity-based skin therapies.
Gero raised $17 million to advance its aging-focused drug discovery platform in June 2026.
When was it?
Gero announced the new financing on 17 June 2026, with industry coverage following during the same week.
Who are they?
Gero uses longitudinal human data, AI and physics-based models of aging to identify therapeutic targets and develop medicines for aging-driven diseases.
Geographical focus?
Gero operates between Singapore and San Francisco while working with pharmaceutical partners internationally.
Why do we include them in the longevity market?
Gero is a direct fit under AI geroscience and longevity drug discovery because its central objective is finding interventions that slow aging biology itself.
What is the company stage?
Gero is at the discovery and preclinical stage with an internal pipeline and established pharmaceutical collaborations.
How much did they raise?
Gero raised $17 million in new equity financing, bringing its reported total equity funding to about $34 million.
What round is it?
Gero described the transaction as new equity financing, while several funding databases classify it as a Series B.
Why did they raise?
Gero raised the capital to advance its preclinical pipeline and expand pharmaceutical collaborations built around its aging-target discovery platform.
Reservoir Neuroscience raised a $3 million Seed extension in June 2026.
When was it?
Reservoir Neuroscience's latest $3 million financing was reported around 17 June 2026.
Who are they?
Reservoir Neuroscience develops small molecules designed to repair aging brain blood vessels and restore blood-brain-barrier function.
Geographical focus?
Reservoir Neuroscience is based in the San Francisco Bay Area and is pursuing U.S.-focused drug development.
Why do we include them in the longevity market?
Reservoir Neuroscience fits aging-brain longevity therapeutics because its platform targets age-related vascular deterioration as an upstream driver of neurodegeneration.
What is the company stage?
Reservoir Neuroscience is at the preclinical drug-development stage.
How much did they raise?
Reservoir Neuroscience raised $3 million in the latest Seed extension.
What round is it?
Reservoir Neuroscience's financing was a Seed extension following earlier Seed funding.
Why did they raise?
Reservoir Neuroscience raised the capital to continue preclinical development of compounds that restore blood-brain-barrier function and advance its lead aging-brain program.
Round sizes say a lot about investor confidence. Our longevity market report tracks every major deal so you don't have to.
Everlab raised about $46 million in a Series A in June 2026.
When was it?
Everlab's Series A was announced on 17 June 2026 in Australia, with international reporting beginning around the same date.
Who are they?
Everlab combines diagnostics, medical history, genetics, wearable data, clinicians and AI to identify health risks early and create personalized preventive-health plans.
Geographical focus?
Everlab is established in Australia, has expanded into New Zealand and is using the new financing to enter the UK.
Why do we include them in the longevity market?
Everlab fits preventive health and longevity because the company originated as a longevity clinic and continues to focus on early detection and extending healthy life through longitudinal care.
What is the company stage?
Everlab is at the growth and product-market-fit stage, with tens of thousands of consultations completed and an expanding international footprint.
How much did they raise?
Everlab raised A$65 million, equivalent to approximately US$46 million at the time of the financing.
What round is it?
Everlab's financing was a Series A round.
Why did they raise?
Everlab raised the capital to enter the UK, expand its clinical and diagnostic infrastructure and continue scaling its AI-supported preventive-health platform.
Price is often what holds a market back. See how fast that's changing in our longevity market report.
Written by the New Market Pitch teamWe track new markets so founders and investors can move faster. About us